Clinical Trials Logo

Filter by:
NCT ID: NCT01599871 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease

ASSET
Start date: January 2011
Phase: Phase 3
Study type: Interventional

The main objective of the study is to determine the effects of low-dose oral theophylline added to combination treatment with long-acting β-agonist (LABA) and inhaled corticosteroid (ICS) in patients with severe Chronic Obstructive Pulmonary Disease (COPD) on the rate of exacerbations defined as increase of symptoms that requires a change of medication (antibiotics and/or systemic glucocorticoid) or hospitalisation. DESIGN: Phase III multicenter, randomized, placebo-controlled, double blind, parallel, prospective study. Patient will be recruited during an hospitalisation due to COPD exacerbation and randomised at the time of discharge to receive theophylline 100 mg or placebo on top of combination therapy with inhaled corticosteroids and long-acting beta agonist. The rate of exacerbations will be determined every three months up to one year follow-up. Cl inic visits: every 3 months (total number of clinic visits = 4). In each of them, the following information will be obtained: - Number/severity of exacerbations or hospitalisation since last clinic visit - Compliance and side effects - Blood sample - Plasma levels of theophylline - Sputum (induced) - MMRC - SGRQ - Forced spirometry + inspiratory capacity - At the beginning and at the end of the study - 6MWT - BMI - BODE

NCT ID: NCT01599806 Completed - Clinical trials for Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis

NCT ID: NCT01599650 Completed - Clinical trials for Branch Retinal Vein Occlusion

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

BRIGHTER
Start date: May 2012
Phase: Phase 3
Study type: Interventional

This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.

NCT ID: NCT01598987 Completed - Liver Transplant Clinical Trials

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This study is designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.

NCT ID: NCT01598831 Completed - Severe Sepsis Clinical Trials

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Start date: October 29, 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.

NCT ID: NCT01598220 Completed - Schizophrenia Clinical Trials

Computer Assisted Cognitive Remediation Program in Schizophrenia

CACREPS
Start date: September 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether computer-assisted cognitive remediation therapy is effective in the treatment of cognitive deficits in schizophrenia.

NCT ID: NCT01598090 Completed - Hepatitis C Virus Clinical Trials

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

PEDESTAL
Start date: June 14, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.

NCT ID: NCT01598077 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Start date: July 2012
Phase: Phase 1
Study type: Interventional

This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer

NCT ID: NCT01597908 Completed - Melanoma Clinical Trials

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

COMBI-v
Start date: June 4, 2012
Phase: Phase 3
Study type: Interventional

This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.

NCT ID: NCT01597752 Completed - Allergy to Mites Clinical Trials

Biological Standardization of Blomia Tropicalis Allergen Extract

Start date: April 2012
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the biologic activity of a Blomia tropicalis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).